Navigation Links
Alexza Pharmaceuticals to Present AZ-004 (Staccato Loxapine),Clinical Data at the Annual NCDEU Meeting

PALO ALTO, Calif., June 05, 2007 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. announced today that it will present at the 47th Annual NCDEU Meeting the results of a Phase I clinical trial of Staccato loxapine (AZ-004), which is being developed for the treatment of acute agitation in patients with schizophrenia. The annual NCDEU meeting is co-sponsored by the National Institute of Mental Health and the American Society of Clinical Psychopharmacology.

The poster presentation, "Novel inhalation technology delivers intravenous-like pharmacokinetics of loxapine in healthy volunteers" (Session 1-93), will be available for viewing at the meeting at the Mizner Center in Boca Raton, Florida on Tuesday, June 12, 2007 from 12:00 to 2:00 pm.

Alexza Pharmaceuticals is an emerging pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. The Company has five product candidates in clinical development; AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches, AZ-004 (Staccato loxapine) for the treatment of acute agitation in patients with schizophrenia, AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder, AZ-003 (Staccato fentanyl) for the treatment of patients with acute pain and AZ-007 (Staccato zaleplon) for the treatment of sleep disorder in patients who have difficulty falling asleep.

CONTACT: Thomas B. King, Pesident & CEO of Alexza Pharmaceuticals, Inc.,+1-650-687-3900,

Web site:

Ticker Symbol: (NASDAQ-NMS:ALXA)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Alexza Pharmaceuticals to Present AZ-001 Phase IIb Clinical Data at the American Headache Society Meeting
2. Alexzas AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating Schizophrenic Patients With Acute Agitation
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
(Date:11/24/2015)... WuXi PharmaTech (Cayman) Inc. ("WuXi" or the ... capability and technology platform company serving the pharmaceutical, biotechnology, ... China and the United States ... meeting of shareholders held today, the Company,s shareholders voted ... the previously announced agreement and plan of merger (the ...
(Date:11/24/2015)... 24, 2015  In the pharmaceutical industry, companies want ... to quickly uncover new insights, tactics and strategies that ... --> However, organizations often find it ... and ensure that all rules and regulations are met ... major barrier to efficiently launching market research projects is ...
(Date:11/24/2015)... , Nov. 24, 2015  DILON Diagnostics and GE ... an agreement for DILON to distribute GE,s Discovery NM750b ... globe. The signing of this distribution agreement will provide Dilon,s ... Breast Imaging system and is considered an initial step ... healthcare solutions for clinicians and their patients. ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... 2015 , ... Chiropractic student Katie Benson received a $2,500 ... Park, Kansas. Benson, a fifth-trimester student in the university’s College of Chiropractic, accepted ... 16. , “Katie is very excited and greatly appreciative to receive the Standard ...
(Date:11/24/2015)... ... November 24, 2015 , ... Sir Grout of ... the TrustDale certification. The award recognizes good companies for excellence in service and ... and grout, and hard surface restoration company earned this recognition after a thorough ...
(Date:11/24/2015)... ... 24, 2015 , ... Bibliomotion is thrilled to announce the launch ... and Diversity by Nancy M. Schlichting, Chief Executive Officer of Henry Ford ... address the needs of patients and their families, shaped my desire to improve the ...
(Date:11/24/2015)... ... , ... Dr. Kevin Day, local family chiropractor in Warsaw , is ... season. During the Indiana winter months, Vitamin D deficiency can lead to Seasonal ... want to help provide the tools needed to combat it this year! , “Stress ...
(Date:11/24/2015)... ... ... life, Don Peck’s mother wondered if she was a descendant of Samuel Fuller, a passenger ... 25-year search for information, Don and his aunt discovered that she was not, in fact, ... it was Don’s father who was descended from not one, but four passengers on the ...
Breaking Medicine News(10 mins):